Darzalex daratumumab: Additional Phase III data

Additional data from the open-label, international Phase III Castor (MMY3004) trial in 498 patients with relapsed or refractory MM showed that median PFS, the primary endpoint, was not reached in patients receiving IV Darzalex plus Velcade bortezomib and dexamethasone vs.

Read the full 409 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE